Last reviewed · How we verify

NCT03782454

Quantification of Bacterial DNA in Sepsis

Status unknown Last updated 29 January 2019
What this trial tests

trial testing Blood sampling in Septic Shock in 60 participants. Status unknown.

Timeline
7 January 2019
Primary endpoint
31 December 2021
31 May 2022

Quick facts

Lead sponsorRegion Örebro County
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date7 January 2019
Primary completion31 December 2021
Estimated completion31 May 2022
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Region Örebro County — full company profile →

Who can join

18 and older, any sex, with Septic Shock or Sepsis Bacterial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate whether bacterial DNA clearance measured with droplet digital Polymerase Chain Reaction (ddPCR) can be used as a measure of bacterial load in septic intensive care patients. Furthermore, the aim is to examine a possible relation between clearance of bacterial DNA and clinical outcome in the septic patient, and the relationship between concentration of beta-lactam antibiotics and the clearance of bacterial DNA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood sampling

Trials testing the same drug.

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

Other Region Örebro County trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03782454.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing